Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
This study, called NRG Promethean, is for men with a type of prostate cancer that has spread to a few other places in the body, but is still responding to hormone treatments. It compares two approaches: receiving standard radiation therapy by itself, or having radiation therapy along with a new study drug called relugolix. Relugolix works by lowering the amount of testosterone in the body, which can help slow down the growth of prostate cancer. Researchers want to find out if adding relugolix to radiation therapy is better at stopping the cancer from spreading further. The study will also look at side effects and how treatments affect men's quality of life.
A colpo d'occhio
Di cosa tratta questo studio?
This study is called the NRG Promethean study and it focuses on men who have prostate cancer that has spread to a limited number of other parts of their body, known as 'oligometastatic' prostate cancer. This type of cancer is still sensitive to treatments that reduce male hormones. Currently, the usual treatment for this is radiation therapy, which uses strong energy beams to kill cancer cells.
The study wants to see if adding an oral drug called relugolix to this standard radiation therapy makes the treatment more effective. Relugolix works by lowering the level of testosterone in the body. Since prostate cancer often relies on testosterone to grow, reducing this hormone can help slow or stop the cancer's growth. The main goal is to find out if combining relugolix with radiation therapy can better prevent new cancer spots from appearing or stop the existing ones from growing.
Researchers will compare men who receive just the radiation therapy with those who receive radiation therapy plus relugolix. They will track key things like how long patients go without their cancer noticeably spreading, their quality of life, and any side effects. This will help doctors understand if this new combination treatment could be a better option for men with this specific type of prostate cancer.
Punti chiave
- This study investigates adding relugolix to standard radiation for specific prostate cancer.
- Relugolix aims to lower testosterone, which can impact prostate cancer growth.
- You might receive the active drug or a placebo, alongside radiation.
- The main goal is to see if the combination better prevents cancer spread.
- Your quality of life and side effects will be carefully monitored.
- Participation involves daily medication for six months and regular check-ups.
Chi può essere idoneo?
This study is looking for men aged 18 or older who have been diagnosed with prostate cancer. This cancer must have spread to a few, limited areas in their bones or other soft tissues of the body, but it's still manageable with hormone treatments. You would have had a specific scan (like a PSMA PET scan) recently to show these areas.
To join, you must have already had previous treatments for your prostate cancer that aimed to cure it, such as surgery (prostatectomy) or radiation therapy to the prostate area. You also need to be generally well enough to take part in the study, as assessed by a quick health check.
However, if your cancer has spread very widely, or if you haven't received prior curative-intent treatment for your prostate, this study might not be suitable for you.
Questo studio potrebbe fare al caso tuo?
Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.
- Are you a man aged 18 or older?
- Do you have prostate cancer that has spread to 1 to 5 spots in your bones or soft tissues?
- Is your prostate cancer still responding to hormone treatments?
- Have you previously had surgery or radiation treatment for your prostate cancer?
- Are you generally well enough to take part in a study?
Cosa comporta la partecipazione?
If you decide to join this study, your involvement would last for about six months of active treatment, with follow-up appointments afterwards. You would be randomly assigned to one of two groups. One group will take a placebo (a dummy pill that looks like the real drug but contains no active medicine) every day for about six months. The other group will take relugolix every day for the same period. Both groups will also receive their usual radiation therapy, which typically lasts for 1 to 3 weeks.
Throughout the study, you'll have various tests and scans, such as bone scans, CT scans, and special PET scans, to monitor your cancer and check how you're responding to treatment. You'll also answer questionnaires about your health and how you're feeling, including questions about your sexual health and general well-being. These assessments will help the study team understand the effects of the treatment and manage any side effects. You'll have regular clinic visits, and the study will oversee your progress and health for an extended period.
Rischi e benefici potenziali
Locations (245)
- Cancer Center at Saint Joseph'sCodice postale verificatoPhoenix, Stati Uniti
- Centro Medico Alta Bates Summit-Campus HerrickCodice postale verificatoBerkeley, Stati Uniti
- Tower Cancer Research FoundationCodice postale verificatoBeverly Hills, Stati Uniti
- Marin General HospitalCodice postale verificatoGreenbrae, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory CareCodice postale verificatoIrvine, Stati Uniti
- Los Angeles General Medical CenterCodice postale verificatoLos Angeles, Stati Uniti
- USC / Norris Comprehensive Cancer CenterCodice postale verificatoLos Angeles, Stati Uniti
- Cedars Sinai Medical CenterCodice postale verificatoLos Angeles, Stati Uniti
- Memorial Medical CenterCodice postale verificatoModesto, Stati Uniti
- UC Irvine Health/Chao Family Comprehensive Cancer CenterCodice postale verificatoOrange, Stati Uniti
- Sutter Medical Center SacramentoCodice postale verificatoSacramento, Stati Uniti
- Sutter Pacific Medical FoundationCodice postale verificatoSanta Rosa, Stati Uniti
Domande comuni
What is 'oligometastatic' prostate cancer?
This means your prostate cancer has spread to a small, limited number of other spots in your body, rather than very widely.
What is relugolix?
Relugolix is a drug that lowers testosterone levels in the body, which can help slow down the growth of prostate cancer cells.
What is a 'placebo'?
A placebo is a dummy pill with no active medicine, used in studies to compare against the active drug and see what real effects the drug has.
How long will I take the study drug?
You would take the study drug (relugolix or placebo) every day for about six months.
Will this study affect my usual doctor’s care?
No, joining a study like this should not affect your regular medical care. Your doctors will work together.
Come saperne di più
Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.
Discussione
Discussione della comunità
Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.